AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01573663 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levodropropizine
Description: Levodropropizine 60mg, PO, single dose
Study NCT01406080 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adapalene
Description: Apply approximately 1 gram of Differin 0.3% every night on the entire face, except near the eye region.
Study NCT01406080 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tretinoin
Description: Apply approximately 1 gram of Tretinoin emollient cream 0.05% every night on the entire face, except near the eye region.
Study NCT01534845 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide (Temodal)
Description: RT with daily temozolomide (75 mg/m2/day, 7 days/week) from the first to the last day of radiotherapy) and adjuvant TMZ chemotherapy (150-200 mg/m2 po qd for 5 days q 28 days for 6 cycles)
Study NCT01875562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qishe Pill
Description: Pill, 3.75 g, twice per day, four weeks
Study NCT04345107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-009
Description: The subjects were admitted to the clinical trial center two days before the administration period (D-2), fasted for 10 hours overnight on the day before the Administration (D-1), and banned water for 1 hour before the administration. Take sy-009 test drug or placebo immediately before meal (QD is before breakfast, bid is before breakfast and dinner) in the morning of the first day of administration, and deliver it with not more than 200ml warm boiled water. From the day 2 (D2) to the day 7 (D7) before dinner, the oral cavity of the subjects was checked for residual drugs after each administration.
Study NCT03024580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole 2.5Mg Tablet
Description: Letrozole 2.5 mg PO daily OR
Study NCT04345107 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SY-009 matching placebo
Description: SY-009 matching placebo
Study NCT01146223 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03024580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane 25 MG
Description: Exemestane 25 mg PO daily
Study NCT03024580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen 20Mg Tablet
Description: Tamoxifen 20 mg PO daily
Study NCT02143258 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stenting of the venous sinus
Description: Patients with medically refractory idiopathic intracranial hypertension who meet the eligibility criteria will be offered stenting of their venous sinus in effort to reduce their intracranial pressure and improve their visual capabilities.
Study NCT03024580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant 50Mg Solution for Injection
Description: Fulvestrant 500 mg IM d1, d14, d28 and q28 days
Study NCT04228822 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet
Description: 25-35% of carbohydrates from total energy intake
Study NCT02485951 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Central air injection
Description: Air was injected inside the trephination site in the central injection group.
Study NCT02485951 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral air injection
Description: Air was injected at the corneal periphery outside the trephination site.
Study NCT01602328 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AC607
Description: AC607 will be a single administration at a target dose of 2 x 10E6 hMSC/kg body weight
Study NCT01602328 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Only
Description: The dose will be calculated and recorded in the same way as for AC607.
Study NCT05806177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD16 30mg、40mg
Description: AD16 was taken continuously.Firstly, a 30 mg (bid) multiple dose study was conducted, followed by a 40 mg (bid) multiple dose study
Study NCT05806177 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AD16 Placebo 30mg、40mg
Description: AD16 placebo was taken continuously.Firstly, a 30 mg (bid) multiple dose study was conducted, followed by a 40 mg (bid) multiple dose study
Study NCT01515163 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Aerobic exercise training, two times a week
Study NCT00005922 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partial schedule of pharmacotherapeutic reinforcement
Description: Dose of 0.1% of Aristocort A on 1-2 of every 4 days for a period of up to 14 weeks.
Study NCT00005922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose control for Arm B
Description: Dose of 0.025-0.05% of Aristocort A 2 times per day for a period of up to 14 weeks.
Study NCT02312427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suspending DPP-4 inhibitor, in outpatient service
Description: After baseline data collection, DPP-4 inhibitor (sitagliptin, vildagliptin, alogliptin, linagliptin, teneligliptin, anagliptin or saxagliptin) will be suspended for one month and serum BNP will be measured. The DPP-4 inhibitor will be resumed and after another month, serum BNP will be measured again.
Study NCT02312427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Starting DPP-4 inhibitor after treatment of heart failure
Description: After hospitalization, medication for diabetes will be suspended. During the treatment for heart failure, drugs other than DPP-4 inhibitor will be resumed when required. After the stabilization of heart failure, DPP-4 inhibitor will be resumed (or administered if it was not prescribed before hospitalization) and serum BNP before and after the initiation of DPP-4 inhibitor will be measured.
Study NCT02509143 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High-dose acupuncture with intravenous infusion of ramosetron
Description: Three sessions of acupuncture will be provided within 48 hours after surgery. Electrical stimulation with an alternating frequency of 2 to 100 Hz will be applied to selected points (PC6 to LI4, ST36 to ST37, and bilateral SP6).~An embedded acupuncture technique for preoperative anxiety will be applied to the bilateral acupuncture points of Liver (LI4), Heart 7 (HT7), Stomach (ST36), Yin-Tang, ear Shen-Men,and ear sympathetic and will be removed the next day. Treatments will be provided by qualified hospital staff (Korean medical doctors) with more than 10 years of clinical experience. The same stimulation of P6 points and antiemetics will be provided to the P6 acupuncture-point stimulation group.
Study NCT02509143 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: P6 stimulation with intravenous infusion of ramosetron
Description: Stimulation of P6 points will be maintained from one hour before and for 48 hours after surgery by wearing a wristband that produces pulse-type transcutaneous electrical stimulation. Antiemetics will be provided, the same as the standard antiemetic medication alone group.
Study NCT02509143 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: P6 stimulation with intravenous infusion of ramosetron
Description: Stimulation of P6 points will be maintained from one hour before and for 48 hours after surgery by wearing a wristband that produces pulse-type transcutaneous electrical stimulation. Antiemetics will be provided, the same as the standard antiemetic medication alone group.
Study NCT02509143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of ramosetron
Description: Intravenous infusion of (oxycodone 20mg, ketorolac 120mg, ramosetron 0.3mg) as standard antiemetic medication will be provided. A dose of continuous infusion will be reduced by 0.1 ml/hr when a patient complaints of nausea.~When vomiting occurs, a dose of continuous infusion will be reduced by 0.2 ml/hr and a bolus infusion of ramosetron 0.3 mg will be provided. A bolus infusion of ramosetron 0.3 mg will be also given if a patient feels greater than or equal to six points of nausea as measured on a 0 to 10 numeric rating scale (NRS) (nausea-severity scale) or by the patient's request, regardless of the severity of the nausea.
Study NCT02509143 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous infusion of ramosetron
Description: Intravenous infusion of (oxycodone 20mg, ketorolac 120mg, ramosetron 0.3mg) as standard antiemetic medication will be provided. A dose of continuous infusion will be reduced by 0.1 ml/hr when a patient complaints of nausea.~When vomiting occurs, a dose of continuous infusion will be reduced by 0.2 ml/hr and a bolus infusion of ramosetron 0.3 mg will be provided. A bolus infusion of ramosetron 0.3 mg will be also given if a patient feels greater than or equal to six points of nausea as measured on a 0 to 10 numeric rating scale (NRS) (nausea-severity scale) or by the patient's request, regardless of the severity of the nausea.
Study NCT01277276 — intervention group
Intervention type: DEVICE
Intervention: Diffuse optical spectroscopy and Near infrared spectroscopy
Description: Diffuse optical spectroscopy and Near infrared spectroscopy are non-invasive methods measure tissue hemodynamics in real time, direct quantitative information and insights treatment-associated toxicity.
Study NCT06556849 — intervention group
Intervention type: DEVICE
Intervention: Defocus Incorporated Multiple Segments (DIMS)
Description: To evaluate the effectiveness of Defocus Incorporated Multiple Segments (DIMS) in slowing myopia progression as a function of age in pediatric patients.
Study NCT02174926 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Elective laparoscopic sigmoid resection
Study NCT02174926 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Conservative treatment
Description: Written lifestyle guidance and fiber supplements
Study NCT03475251 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CS1003
Description: In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme. In the dose expansion part, patients will be assigned to different groups based on their tumor type.
Study NCT03475251 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CS1003
Description: CS1003 to be intravenously administered at the dose level determined during the dose escalation part
Study NCT03475251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Regorafenib to be orally administered at the protocol-specified dose level, once daily for the first 21 days of each 28-day cycle
Study NCT00480038 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: WHODAS II
Description: To determine the measurement characteristics of WHODAS II (World Health Organization Disability Assessment Schedule)
Study NCT02512900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI9929, 140 mg
Description: On Day 1, two MEDI9929 subcutaneous injection of 70 mg each were given into the anterior aspect of one thigh immediately followed by the second injection into the anterior aspect of the contralateral thigh to make the required dose of 140 mg in participants of 12 to 17 years of age.
Study NCT02312427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suspending DPP-4 inhibitor after treatment of heart failure
Description: After hospitalization, medication for diabetes may be suspended or continued. During the treatment for heart failure, drugs including DPP-4 inhibitor will be resumed when required. After the stabilization of heart failure, DPP-4 inhibitor will be suspended and serum BNP before and after the suspension of DPP-4 inhibitor will be measured.
Study NCT00005922 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard pharmacotherapeutic protocol
Description: Full dose of Aristicort A (0.1%) 2 times per day for a period of up to 14 weeks.
Study NCT03774472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Given PO
Study NCT03774472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Given PO
Study NCT03774472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Given PO
Study NCT02417337 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Root Canal Treatment
Description: A standardized endodontic procedures performed.
Study NCT02417337 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root Canal Treatment
Description: A standardized endodontic procedures performed.
Study NCT02991196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-8273a + nivolumab
Description: Nivolumab will be administered at 240 mg intravenously (IV) once every two weeks (Q2W) over 30 (± 5) minutes (on Days 1 and 15 of each cycle of 28 days). DS-8273a will be administered \[90 (± 15) minutes on Day 1 of Cycle 1, and 60 (± 15) minutes in subsequent infusions\] after the end of the nivolumab infusion in ascending doses up to 1200 mg IV Q2W. The regimen is adjusted based on injection site reactions or adverse events. Additional dose combinations may be considered based on the assessment of safety, primary pharmacodynamic (PDy) effects, and preliminary anti-tumor activities.
Study NCT00660660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Nexium 20 mg administered once daily as 22.3 mg of esomeprazole magnesium hydrate
Study NCT02417337 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Root Canal Treatment
Description: A standardized endodontic procedures performed.
Study NCT02417337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Study NCT02417337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Study NCT00660660 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily
Study NCT03835468 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Galacto-oligosaccharides
Description: GOS is a form of prebiotic, which enhance the growth of beneficial gut bacteria
Study NCT03835468 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: sugar based placebo
Study NCT03130335 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BMA Injection
Description: Bone marrow will be aspirated from the iliac crest and injected into the knee.
Study NCT03130335 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMA
Description: Bone marrow will be aspirated from the iliac crest.
Study NCT03018990 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ethanol
Description: 1 milliliter per kilogram body weight adjusted for elevated body mass index
Study NCT01604239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shinbaro Capsule
Description: 600mg twice a day (b.i.d) oral herbal medicine
Study NCT03810937 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: head position
Description: head positioning in sniffing or flat position
Study NCT02417337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Study NCT01165047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: Nitric oxide, 80 ppm in air or oxygen will be administered using the GeNO nitrosyl delivery system with a standard nasal cannula at a flow rate of 4 LPM.
Study NCT01238796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telavancin
Description: Intravenous
Study NCT01317849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: 0.8mg
Study NCT01317849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin B6
Description: 10mg
Study NCT01317849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Description: 500ug
Study NCT01317849 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 0.8 mg
Study NCT01317849 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 10mg
Study NCT02741895 — intervention group
Intervention type: BEHAVIORAL
Intervention: Fitbit monitoring
Description: Patients will be fitted with a Fitbit after surgery, which will monitor steps and active minutes for the duration of hospitalization.
Study NCT02417337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mefenamic acid
Study NCT02417337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac
Study NCT02816970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: 1 tablet contains 50 mg vildagliptin
Study NCT02816970 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vildagliptin
Description: 1 tablet contains 50 mg vildagliptin
Study NCT03013413 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Shear Wave Elastography
Description: Undergo ultrasound-based elastography imaging using the Aixplorer system
Study NCT03013413 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Elasticity Imaging
Description: Undergo ultrasound-based elastography imaging using the Aixplorer system
Study NCT03013413 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-Guided Prostate Biopsy
Description: Undergo standard of care ultrasound-guided prostate biopsy
Study NCT02663921 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Part A: Baseline-Week 2
Description: The study doctor will shine 2 different light bulbs (one a regular or incandescent bulb and the other an LED light bulb) on 12 different areas of patients skin approximately 6 square centimeters in size (less than 1 square inch or the size of your thumb nail). Each light bulb will be exposed to your skin for approximately 20 - 35 minutes. After exposure, the study doctor will perform skin assessments at 3 time points:~1. Immediately after the light exposure;~2. 30 minutes after light exposure; and~3. 1 hour after light exposure.
Study NCT02663921 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Part B: Week 4-Week 12
Description: The study doctor will perform the same 4 skin assessments used in Part A at each visit to assess potential changes in your skin: Digital Photography~1. Visual Clinical Assessment~2. Spectroscopy~3. Colorimetry
Study NCT03115697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose
Description: Lactulose 20 mL
Study NCT05112068 — intervention group
Intervention type: OTHER
Intervention: traditional skin care method
Description: Skin and hair care for critically ill patients will be carried out using traditional means: clean warm water, cotton diapers and napkins, liquid soap, 0.02% aqueous chlorhexidine solution, and regular shampoo.
Study NCT05112068 — intervention group
Intervention type: OTHER
Intervention: method using specialized gloves
Description: Specialized hygienic gloves soaked in a washing lotion Aqua Total Hygiene (Cleanis, France) for skin care and Aqua Shampoo (Cleanis, France) for hair care will be used.~According to the manufacturer's recommendation, six hygienic gloves should be used for one skin care procedure, and two gloves should be used for hair care. The care method used in the experimental group will not require additional rinsing and drying.
Study NCT04561531 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3%NaCl
Description: Intervention is infusion of 3%NaCl which is defined in arms of experiment.
Study NCT03080714 — intervention group
Intervention type: DEVICE
Intervention: Topcon DRI OCT Triton (plus)
Description: The Topcon DRI OCT Triton (plus) is an OCT machine used for diagnostic purposes
Study NCT03080714 — intervention group
Intervention type: DEVICE
Intervention: 3D OCT-1 Maestro
Description: The 3D OCT-1 Maestro is an OCT machine used for diagnostic purposes
Study NCT01317849 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 500ug
Study NCT04599790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TACE combined with lenvatinib and sintilimab
Description: Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight \<60kg) P.O. qd and sintilimab 200mg I.V. q3w will be started at 3-7 days after the first TACE.TACE will be repeated if clinically indicated. Treatment of sintilimab will last up to 24 months. Patients will be allowed to have lenvatilib or sintilimab as a sigle agent and will be still considered on study when the other drug cause intolerable toxicity.
Study NCT00884507 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: po daily for 24 weeks
Study NCT00884507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5313534
Description: 1mg po daily for 24 weeks
Study NCT00884507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5313534
Description: 5mg po daily for 24 weeks
Study NCT00884507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5313534
Description: 15mg po daily for 24 weeks